WCM Investment Management LLC Takes $6.03 Million Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

WCM Investment Management LLC acquired a new position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 241,894 shares of the company’s stock, valued at approximately $6,030,000. WCM Investment Management LLC owned about 0.28% of IDEAYA Biosciences at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the stock. FMR LLC raised its holdings in IDEAYA Biosciences by 12.1% in the third quarter. FMR LLC now owns 12,635,653 shares of the company’s stock worth $400,297,000 after purchasing an additional 1,365,570 shares in the last quarter. Janus Henderson Group PLC lifted its position in IDEAYA Biosciences by 26.7% during the third quarter. Janus Henderson Group PLC now owns 5,162,376 shares of the company’s stock valued at $163,518,000 after acquiring an additional 1,086,356 shares during the last quarter. State Street Corp boosted its stake in IDEAYA Biosciences by 15.4% in the third quarter. State Street Corp now owns 3,317,936 shares of the company’s stock valued at $105,112,000 after acquiring an additional 443,640 shares in the last quarter. Geode Capital Management LLC grew its holdings in IDEAYA Biosciences by 9.8% in the third quarter. Geode Capital Management LLC now owns 1,945,455 shares of the company’s stock worth $61,645,000 after purchasing an additional 172,838 shares during the last quarter. Finally, RA Capital Management L.P. acquired a new position in shares of IDEAYA Biosciences during the third quarter worth $42,681,000. Institutional investors own 98.29% of the company’s stock.

Analysts Set New Price Targets

IDYA has been the topic of several research analyst reports. Stephens began coverage on IDEAYA Biosciences in a research note on Monday, November 18th. They set an “overweight” rating and a $51.00 target price on the stock. UBS Group began coverage on shares of IDEAYA Biosciences in a report on Thursday, October 24th. They set a “buy” rating and a $50.00 price objective on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Leerink Partners downgraded IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $41.00 to $27.00 in a research note on Tuesday, November 5th. Finally, Leerink Partnrs cut IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 5th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $53.67.

IDEAYA Biosciences Trading Down 4.0 %

IDEAYA Biosciences stock opened at $23.00 on Monday. The firm has a market cap of $1.99 billion, a PE ratio of -9.87 and a beta of 0.82. IDEAYA Biosciences, Inc. has a 12 month low of $22.10 and a 12 month high of $47.74. The stock’s 50 day simple moving average is $24.94 and its two-hundred day simple moving average is $30.61.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.